Short-term and Maintenance Oral Corticosteroid Use for German Patients with Asthma

Le résumé fourni par la source

Introduction: Characterization of regional variation in asthma treatment across Germany will improve understanding of real-world therapy and inform physician education. We aimed to describe regional variation in asthma prevalence and oral corticosteroid (OCS) use in Germany. Methods: We developed a machine learning gradient boosted tree model, with 91% accuracy in predicting the presence of asthma and chronic obstructive pulmonary disease, using IMS ® Disease Analyzer electronic medical records, which cover 3% of German patients. This model was applied to the IMS Longitudinal Prescription database, with 75% national coverage, to classify patients receiving airflow obstruction treatment from Oct 2017 to Sept 2018 in 63 regions. Results: Of 2.4 million patients predicted to have asthma, 13.7%, 18.7%, 36.5%, 29.4%, and 1.7% were categorized as Global Initiative for Asthma (GINA) stages 1, 2, 3, 4, and 5, respectively. At least one short-term OCS prescription was received by 7 – 15% of patients in GINA stages 1 – 4 and 35% of patients in stage 5. At least one maintenance OCS prescription was received by 1 – 3% of patients in GINA stages 1 – 4 and 86% in stage 5. Cumulative OCS dosage and percentage of OCS-treated patients differed substantially across regions ([ Fig. 1 ]). Regions with less maintenance OCS use had greater biologic use. Fig. 1 Cumulative Annual OCS Dosage (mg Prednisolone per Patient with Prescription) for OCS-Treated Patients with Asthma. OCS, oral corticosteroids; Rx, prescription. Conclusions: Maintenance and short-term OCS use varied across Germany and were greater than recommended by guidelines across the spectrum of asthma severity.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.